Francesca Palandri: Prioritizing Anemia Matters in Myelofibrosis
Francesca Palandri, Hematologist at Sant’Orsola-Malpighi Polyclinic – Bologna University Hospital, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Clinical Lymphoma, Myeloma and Leukemia, adding:
“Prioritizing anemia matters in myelofibrosis.
Happy to share our latest subgroup analysis from the phase III SIMPLIFY-1 trial, now published in Clinical Lymphoma, Myeloma Leukemia.
We examined momelotinib vs. ruxolitinib in JAK inhibitor–naive myelofibrosis patients with anemia (Hb 10 g/dL).
Key Findings:
- Momelotinib achieved higher dual response rates (spleen reduction and transfusion independence) vs. ruxolitinib: 27% vs. 7%
- In patients with platelets 200 × 10⁹/L, momelotinib showed superior spleen response: 39% vs. 17%
- Transfusion independence correlated with significantly improved overall survival (HR 0.25–0.40)
Prioritizing transfusion independence in anemic MF patients and suggest momelotinib may be preferred in those with lower platelet counts.
Honored to serve as first author of this collaborative work together with an outstanding group of colleagues.
A big thank-you to all my colleagues at IRCCS Policlinico di Sant’Orsola – Azienda Ospedaliero Universitaria di Bologna.”
Title: Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1
Authors: Francesca Palandri, Nicolaas P M Schaap, Jerome Rey, Nikolas von Bubnoff, Andreas Reiter, Juan Carlos Hernandez-Boluda, Timothy Devos, Lars Nilsson, Bethan Psaila, Donal P McLornan, Bryan Strouse, Shiyuan Zhang, Bharat Patel, Jessica Lim, Dwaipayan Patnaik, Stephen T Oh
Stay updated on all scientific advances with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers